Newsbenzinga
What's Going On With BioVie Stock on Tuesday?
· Published
Article summary
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
An excerpt from the original article.
Comments —
Loading comments…